top of page

The CEO of Arbutus (interim) describes the company's work in hepatitis B and highlights recent EASL data

  • Jun 20, 2024
  • 1 min read

Michael McElhaugh describes data presented at EASL for the RNAi therapeutics imdusiran, explains the rationale for using a small molecule PD-L1 inhibitor against hepatitis B, and more.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

bottom of page